MMTC Annoucement - CIMIT MAIN

Responsive Image
The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

Programs and Offerings

News and Events

null MMTC Annoucement

NIH Lauches MakeMyTestCount

COVID-19 testing remains an essential tool as the United States heads into the holiday season and people navigate respiratory viruses. While taking a rapid COVID-19 test has become commonplace, these test results are not often reported. COVID-19 test results provide valuable data that public health departments can use to assess the needs and modify the responses in the local community, the state, or the nation. 

Reporting a positive or negative test result just became easier. The Rapid Acceleration of Diagnostics (RADx®) Tech program has launched MakeMyTestCount.org, a way to anonymously report the results of any brand of at-home COVID-19 test in a secure manner.

Check out the website here.

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, CIMIT has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.